CN108720016A - 一种养护视力脑力的组合物及其制备方法和应用 - Google Patents
一种养护视力脑力的组合物及其制备方法和应用 Download PDFInfo
- Publication number
- CN108720016A CN108720016A CN201810582800.7A CN201810582800A CN108720016A CN 108720016 A CN108720016 A CN 108720016A CN 201810582800 A CN201810582800 A CN 201810582800A CN 108720016 A CN108720016 A CN 108720016A
- Authority
- CN
- China
- Prior art keywords
- parts
- mental
- extract
- powder
- sight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000003340 mental effect Effects 0.000 title claims abstract description 59
- 238000002360 preparation method Methods 0.000 title claims abstract description 30
- 239000000203 mixture Substances 0.000 title claims abstract description 24
- 239000000284 extract Substances 0.000 claims abstract description 85
- 239000000843 powder Substances 0.000 claims abstract description 55
- 210000000582 semen Anatomy 0.000 claims abstract description 27
- 240000008866 Ziziphus nummularia Species 0.000 claims abstract description 25
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims abstract description 25
- 239000002994 raw material Substances 0.000 claims abstract description 22
- 235000009754 Vitis X bourquina Nutrition 0.000 claims abstract description 19
- 235000012333 Vitis X labruscana Nutrition 0.000 claims abstract description 19
- 235000014787 Vitis vinifera Nutrition 0.000 claims abstract description 19
- 229940106134 krill oil Drugs 0.000 claims abstract description 18
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 17
- 244000068988 Glycine max Species 0.000 claims abstract description 17
- 240000006365 Vitis vinifera Species 0.000 claims abstract 5
- 230000004438 eyesight Effects 0.000 claims description 32
- 235000009508 confectionery Nutrition 0.000 claims description 30
- 238000012423 maintenance Methods 0.000 claims description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 19
- 239000008213 purified water Substances 0.000 claims description 19
- 239000000706 filtrate Substances 0.000 claims description 15
- 238000001914 filtration Methods 0.000 claims description 15
- 229920002774 Maltodextrin Polymers 0.000 claims description 13
- 239000005913 Maltodextrin Substances 0.000 claims description 13
- 229940035034 maltodextrin Drugs 0.000 claims description 13
- 238000001035 drying Methods 0.000 claims description 12
- 241000234435 Lilium Species 0.000 claims description 11
- 235000019441 ethanol Nutrition 0.000 claims description 10
- 239000011122 softwood Substances 0.000 claims description 10
- 238000009501 film coating Methods 0.000 claims description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 8
- 238000002137 ultrasound extraction Methods 0.000 claims description 8
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical group OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 7
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims description 7
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims description 7
- 241000724115 Ziziphus lotus Species 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 239000007888 film coating Substances 0.000 claims description 7
- 235000013305 food Nutrition 0.000 claims description 6
- 238000005469 granulation Methods 0.000 claims description 6
- 230000003179 granulation Effects 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 6
- -1 Flavine ester Chemical class 0.000 claims description 5
- 239000006071 cream Substances 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 235000019359 magnesium stearate Nutrition 0.000 claims description 4
- 239000011248 coating agent Substances 0.000 claims description 3
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 3
- 235000013824 polyphenols Nutrition 0.000 claims description 3
- 238000000576 coating method Methods 0.000 claims description 2
- 239000003094 microcapsule Substances 0.000 claims description 2
- 238000004090 dissolution Methods 0.000 claims 1
- 230000036541 health Effects 0.000 abstract description 7
- 210000004185 liver Anatomy 0.000 abstract description 6
- 210000000952 spleen Anatomy 0.000 abstract description 4
- 230000001147 anti-toxic effect Effects 0.000 abstract description 3
- 238000005516 engineering process Methods 0.000 abstract description 3
- 239000000932 sedative agent Substances 0.000 abstract description 3
- 230000001624 sedative effect Effects 0.000 abstract description 3
- 239000005452 food preservative Substances 0.000 abstract description 2
- 235000019249 food preservative Nutrition 0.000 abstract description 2
- 210000002784 stomach Anatomy 0.000 abstract 1
- 238000005728 strengthening Methods 0.000 abstract 1
- 241000219095 Vitis Species 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 239000000047 product Substances 0.000 description 13
- 210000004556 brain Anatomy 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 238000001694 spray drying Methods 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 7
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 235000016709 nutrition Nutrition 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 5
- 230000035764 nutrition Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 4
- 206010047513 Vision blurred Diseases 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 208000003464 asthenopia Diseases 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 229910052749 magnesium Inorganic materials 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 230000035807 sensation Effects 0.000 description 4
- 235000019615 sensations Nutrition 0.000 description 4
- 239000011573 trace mineral Substances 0.000 description 4
- 235000013619 trace mineral Nutrition 0.000 description 4
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000000686 essence Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 206010022437 insomnia Diseases 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 206010025482 malaise Diseases 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 230000001603 reducing effect Effects 0.000 description 3
- 229930003352 steroid alkaloid Natural products 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001256 tonic effect Effects 0.000 description 3
- 230000002936 tranquilizing effect Effects 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 206010034960 Photophobia Diseases 0.000 description 2
- 206010039966 Senile dementia Diseases 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000006694 eating habits Nutrition 0.000 description 2
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 229930182478 glucoside Natural products 0.000 description 2
- 150000008131 glucosides Chemical class 0.000 description 2
- 239000004519 grease Substances 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 210000002189 macula lutea Anatomy 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000003507 refrigerant Substances 0.000 description 2
- 229930002534 steroid glycoside Natural products 0.000 description 2
- 150000008143 steroidal glycosides Chemical class 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 206010057315 Daydreaming Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- AJPXZTKPPINUKN-UHFFFAOYSA-N Isoliensinin Natural products C1=CC(OC)=CC=C1CC1C2=CC(OC=3C(=CC=C(CC4C5=CC(O)=C(OC)C=C5CCN4C)C=3)O)=C(OC)C=C2CCN1C AJPXZTKPPINUKN-UHFFFAOYSA-N 0.000 description 1
- AJPXZTKPPINUKN-FIRIVFDPSA-N Isoliensinine Chemical compound C1=CC(OC)=CC=C1C[C@@H]1C2=CC(OC=3C(=CC=C(C[C@@H]4C5=CC(O)=C(OC)C=C5CCN4C)C=3)O)=C(OC)C=C2CCN1C AJPXZTKPPINUKN-FIRIVFDPSA-N 0.000 description 1
- XCUCMLUTCAKSOZ-FIRIVFDPSA-N Liensinine Chemical compound C([C@@H]1C=2C=C(C(=CC=2CCN1C)OC)OC=1C(O)=CC=C(C=1)C[C@H]1N(C)CCC=2C=C(C(=CC=21)OC)OC)C1=CC=C(O)C=C1 XCUCMLUTCAKSOZ-FIRIVFDPSA-N 0.000 description 1
- XCUCMLUTCAKSOZ-JSOSNVBQSA-N Liensinine Natural products C([C@@H]1C=2C=C(C(=CC=2CCN1C)OC)OC=1C(O)=CC=C(C=1)C[C@@H]1N(C)CCC=2C=C(C(=CC=21)OC)OC)C1=CC=C(O)C=C1 XCUCMLUTCAKSOZ-JSOSNVBQSA-N 0.000 description 1
- YXVXMURDCBMPRH-UHFFFAOYSA-N Lirinidine Natural products C1C2=CC=CC=C2C2=C(O)C(OC)=CC3=C2C1N(C)CC3 YXVXMURDCBMPRH-UHFFFAOYSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- ORJVQPIHKOARKV-UHFFFAOYSA-N Nuciferine Natural products C1C2=CC=CC=C2C2=C(OC)C(OC)=CC3=C2C1N(C)CC3 ORJVQPIHKOARKV-UHFFFAOYSA-N 0.000 description 1
- 244000197580 Poria cocos Species 0.000 description 1
- 235000008599 Poria cocos Nutrition 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 201000007737 Retinal degeneration Diseases 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000007244 Zea mays Nutrition 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000001994 activation Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000036523 atherogenesis Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 230000009246 food effect Effects 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 230000004483 macular pigment optical density Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- ORJVQPIHKOARKV-OAHLLOKOSA-N nuciferine Chemical compound C1C2=CC=CC=C2C2=C(OC)C(OC)=CC3=C2[C@@H]1N(C)CC3 ORJVQPIHKOARKV-OAHLLOKOSA-N 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 description 1
- 150000003906 phosphoinositides Chemical class 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008542 thermal sensitivity Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
- 230000010148 water-pollination Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/40—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds characterised by the fats used
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/42—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds characterised by the carbohydrates used, e.g. polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/48—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing plants or parts thereof, e.g. fruits, seeds, extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
- A23L3/34—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals
- A23L3/3454—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals in the form of liquids or solids
- A23L3/3463—Organic compounds; Microorganisms; Enzymes
- A23L3/3562—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Botany (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明涉及保健品技术领域,具体公开一种养护视力脑力的组合物及其制备方法和应用。所述组合物包括以下重量份数配比的原料:酸枣仁提取物:10‑13份,百合提取物:6.5‑8.5份,莲子提取物:6.5‑8.5份,改性大豆磷脂粉:6.5‑8.5份,磷虾油粉:2.5‑4.5份,叶黄素酯:1.5‑3.5份,白葡萄粉:1‑4份。本发明所提供的养护视力脑力的组合物,通过科学配伍,充分发挥各原料件的互相协调作用,不仅能疏肝名目,养血补肝,宁心安神,清热除烦,健脾养胃,且未使用任何食品防腐剂,食用安全。
Description
技术领域
本发明涉及生物健康食品技术领域,尤其涉及一种养护视力脑力的组合物及其制备方法和应用。
背景技术
处于网络信息时代的白领阶层(脑力劳动人群)视力、脑力健康风险不容忽视,其主要体现在:一是从业压力日渐加大,几乎每天面对电脑的办公方式,以及长期繁重、复杂的脑力劳动;二是饮食习惯影响,例如部分职业女性或特殊职业人群长期保持低糖、低脂类饮食习惯,导致营养不良、脑部及眼部营养缺失;三是不良的生活习惯,尤其是将手机作为日常休闲娱乐方式的人群(2012年的一项调查显示,中国人每天花在手机上的平均时间为3小时,位居全球第二)。长期繁重的脑力消耗会招致大脑血液和氧气供应不足,削弱了脑细胞的正常功能,加之不良的用眼习惯,白领阶层常出现眼疲劳、眼干涩、异物感、眼皮沉重感、视物模糊、畏光流泪、眼胀痛及眼部充血等情况,严重者可能导致头痛、头昏、恶心、精神萎靡、注意力不集中、记忆力下降、以及食欲不振等症状。
脑力与视力下降通常以亚健康状态在人群中表现,因此除非症状严重或已直接诱发其他疾病,一般不建议治疗(从治疗费用及用药风险等药物经济学考虑),目前市场上用于脑力补充或视力改善的产品多为保健食品或具有特殊营养成分添加的功能性食品,其针对的多数为脑力或视力等单一的症状,而其改善脑力、视力的通常也是单一的作用机制(例如单纯的营养补充,或单纯的中医验方调理等)。中西医结合将传统的中医中药知识和方法与现代医学相结合,综合提升临床治疗效果,并阐明机理进而获得新的医学认识。近年来,中西医结合的理论和思路也在逐步引入和影响日常饮食和保健领域,即将中医养生理论与现代分子营养学相结合,在宏观实施中医养生、保健的基础上,优化和改善人体通过日常膳食的营养结构,进而达到亚健康调理、预防疾病的作用。
发明内容
针对现有脑疲劳与视疲劳的相关产品单一性等问题,本发明提供一种养护视力脑力的组合物。
以及,本发明还提供上述养护视力脑力的组合物在制备养护视力脑力食品中的应用。
以及,本发明还提供一种视力脑力养护压片糖果。
以及,本发明还提供一种视力脑力养护压片糖果的制备方法。
为达到上述发明目的,本发明实施例采用了如下的技术方案:
一种养护视力脑力的组合物,包括以下重量份数配比的原料:酸枣仁提取物:10-13份,百合提取物:6.5-8.5份,莲子提取物:6.5-8.5份,改性大豆磷脂粉:6.5-8.5份,磷虾油粉:2.5-4.5份,叶黄素酯:1.5-3.5份,白葡萄粉:1-4份。
相对于现有技术,本发明将脑部营养优化作为脑力、视力改善的统一技术核心,所提供的视力脑力养护压片糖果,组方配伍以宁心安神为主,养血疏肝、气血双补为辅,释放和减轻日常用脑压力,强化自身脑部休养及恢复能力,进而通过改性大豆磷脂、磷虾油粉、叶黄素酯等可直接作用于脑部的脂类营养成分,调节和改善脑部营养,从而达到脑力、视力双补的效果。且本发明产品未使用任何食品防腐剂,原料均为药食同源或一般性食品级原料,可作为日常安全、健康的营养补充剂食用。
酸枣仁提取物,甘、酸、平,入心、肝、胆经。具有养心益肝、宁心安神、敛汗,生津的功效。酸枣仁提取物在本品中的作用:①镇静,同时还可以止痛、降温之效;②治失眠,治疗失眠而言有着非同一般的疗效;③养肝益气,具备补中益气,强健筋骨之效;④酸枣仁能够扩大人体微细血管的直径,对整个人体的微循环起到改善作用。
百合提取物,甘、寒,归心肺经养阴润肺,清心安神,润燥清热,含有磷脂类、酚酸甘油酯、甾体糖苷、甾体生物碱、蛋白质、氨基酸等多种成份。百合提取物在本品中的作用:百合提取物含有人体所需的多种维生素,矿物质及糖、铁、钙等微量元素,具有极高的药用价值,清凉润肺,去火安神。
莲子提取物,性平、味甘涩,入心、脾、肾经,补脾止泻,益肾涩清,养心安神,显著的强心作用,能扩张外周血管,降低血压,还有很好的祛心火的功效,并有助于睡眠。莲子提取物在本品中的作用:①莲子提取物中的钙、磷、钾含量非常丰富,每公斤莲子中含有蛋白质81.3克,脂肪9.8克,糖304毫克,钙436毫克,磷1.397毫克,铁31.4毫克,还含有其他多种维生素、微量元素、荷叶碱、金丝草甙等物质,除可以构成骨骼和牙齿的成分外,还有促进凝血,使某些酶活化,维持神经传导性,镇静神经,维持肌肉的伸缩性和心跳的节律等作用,对治疗神经衰弱有一定功效,丰富的磷还是细胞核蛋白的主要组成部分,帮助机体进行蛋白质、脂肪、糖类代谢,并维持酸碱平衡;②脑力劳动者经常食用,可以健脑,增强记忆力,提高工作效率,并能预防老年痴呆的发生;③含有莲心碱、异莲心碱等多种生物碱,有清热泻火之功能,还有显著的强心作用,能扩张外周血管,降低血压,有助于睡眠,用作补益药,补脾止泻,益肾涩精,养心安神。
改性大豆磷脂粉,主要成分有磷酸胆碱、磷酸胆胺、磷脂酸和磷酸肌醇;有较好的亲水性和水包油乳化功能,能将各组分充分混合分散,代替纯油脂,有改进食品质量、节约食品加工用油的效果,同时具有较强的抗氧化性,防止本发明产品变质。
磷虾油粉,含有大量蛋白质以及人体组织所必需的氨基酸和维生素A,含有Omega-3必需脂肪酸二十碳五烯酸(EPA)和二十二碳六烯酸(DHA)。磷虾油粉在本品中的作用:①降低胆固醇、预防脑溢血、脑血栓,降低血液黏稠度、促进血液循环,预防高血压,健脑益智,活跃思维,预防老年痴呆症;②保护神经细胞膜,增强注意力和记忆力、理解力;③支持视力健康。
叶黄素酯在本品中的作用:①补充人眼视网膜黄斑区域黄斑色素密度,保护黄斑,促进黄斑发育;②保护眼睛不受光线损害,延缓眼睛的老化及防止病变;③抗氧化,有助于预防机体衰老引发的心血管硬化、冠心病和肿瘤疾病;④保护视力,缓解视疲劳症状;(视物模糊、眼干涩、眼胀、眼痛、畏光等);⑤预防黄斑变性及视网膜色素变性,减少玻璃膜疣的产生。
白葡萄粉中含有萄多酚,能抗氧化、抗过敏、延缓皮肤衰老,兼有抑制血小板聚集和动脉粥样硬化形成的作用。
具体的,优选地,包括以下重量份数配比的原料:酸枣仁提取物:11.54份,百合提取物:7.69份,莲子提取物:7.69份,改性大豆磷脂粉:7.69份,磷虾油粉:3.85份,叶黄素酯:2.77份,白葡萄粉:2份。
优选地,所述酸枣仁提取物的制备方法如下:
将酸枣仁洗净、烘干、粉碎过80目筛,以8-12倍量的纯化水浸泡6-8h,煎煮2-3次,每次2-3h,合并煎煮液,过滤,将滤液在真空度为-0.06Mpa~-0.08Mpa,温度为60~65℃条件下减压浓缩,得到相对密度为1.08-1.12膏粉状酸枣仁提取物。
所述加纯化水的质量为物料质量的8~12倍,该水量足以浸透原料组分,且不会因水量过大而使溶液过稀、延长后续浓缩和干燥的时间;所述浸泡为浸泡6-8h,经过浸泡的原料药更容易被提取;所述煎煮为煎煮2-3h,优选的煎煮时间可以使原料药中的有效成分被充分提取出来,时间过短则提取不充分,造成原料的浪费,时间过长并不会明显提高提取率,但会延长生产时间,增加生产成本。
在优选的温度范围内进行减压浓缩和减压干燥,可以提高干燥效率,节约生产成本。
优选地,所述百合提取物的制备方法如下:
将百合洗净、烘干、粉碎过60目筛,以8-10倍量的纯化水浸泡6-8h,采用超声萃取1-2次,每次功率为400-500W,每次超声时间为15-20min,过滤,将滤液在喷雾干燥得到百合提取物。
采用纯化水超声提取,超声提取不需要高温加热,避免高温破坏百合中的营养成分,优选用量倍数浓度及用量范围的纯化水可以使百合粉体中的磷脂类、酚酸甘油酯、甾体糖苷、甾体生物碱、蛋白质、氨基酸等脂溶性成分和水溶性成分均被提取出来,从而清凉润肺,去火安神。
所述超声提取的时间为15-20min,在该时间范围内,百合中前子壳粉中的磷脂类、酚酸甘油酯、甾体糖苷、甾体生物碱、蛋白质、氨基酸等有效成分可以被大部分提取出来,时间太短则有可能提取量太少,降低效果,时间太多则增加时间成本。
优选地,所述莲子提取物的制备方法如下:
将莲子洗净、烘干,粉碎,以8-12倍量的纯化水浸泡6-8h,然后于80-100℃提取2-3次,每次3-4h,合并提取液,过滤,将滤液在喷雾干燥得到莲子提取物。
所述加纯化水的质量为物料质量的8~12倍,该水量足以浸透原料组分,且不会因水量过大而使溶液过稀、延长后续浓缩和干燥的时间;所述浸泡为浸泡6-8h,经过浸泡的原料药更容易被提取;优选为80-100℃提取3-4h,可以使原料药中的有效成分被充分提取出来,提取时间过短则提取不充分,造成原料的浪费,时间过长并不会明显提高提取率,但会延长生产时间,增加生产成本。
优选地,所述叶黄素酯为含量为5-10wt%的叶黄素酯微囊或叶黄素酯粉末。
优选地,所述白葡萄粉中总多酚含量为70-74wt%。
进一步地,本发明还提供上述的养护视力脑力的组合物在制备养护视力脑力食品中的应用。将养护视力脑力的组合物制成食品后,更适宜食用者服用,提高食用者的口感满意度和便捷度,便于长期食用,达到养护视力脑力的效果。
进一步地,本发明一种视力脑力养护压片糖果,包括上述养护视力脑力的组合物。上述组合物适宜制备成压片糖果,且制成压片糖果后,更便于服用。
优选地,所述的视力脑力养护压片糖果,还包括以下重量份数配比的原料:山梨糖醇:25-30份,麦芽糊精:22-27份,硬脂酸镁:0.5-1.5份,薄膜包衣剂:1-3份。
麦芽糊精不含蛋白及膳食纤维,甜度低,无异味,易消化,低热,溶解性好,发酵性小,易被人体吸收,并含有钙、铁等对人体有益的微量元素及矿物质,有助于粉末状产品更快而均匀地分散在介质中,具有速溶增稠效果,可避免沉淀分层现象,并能吸收豆腥味或奶膻味,并能促进人体正常的物质代谢,麦芽糊精还具有不易吸潮、难以变质的特性,是良好的填充料,有助于延长产品保持期。
进一步地,本发明还提供一种视力脑力养护压片糖果的制备方法,至少包括以下步骤:
步骤A、按照上述的原料配比称取各组分;
步骤B、将所述酸枣仁提取物、百合提取物、莲子提取物、改性大豆磷脂粉、磷虾油粉、叶黄素酯、白葡萄粉、麦芽糊精采用三维混合机,混合28-32min,得到预混料;
步骤C、将所述预混料与体积浓度为75-85%的乙醇混合制得软材,且所述预混料与乙醇的质量比为10:(2.5-3.5),将所述软材过16目筛制粒、干燥、过14目筛整粒,得到颗粒;
步骤D、将所述山梨糖醇、硬脂酸镁与所述颗粒采用三维混合机,混合18-22min总混处理,得到总混料;
步骤E、将所述总混料压片,得到素片,素片直径为11.5mm-12.5mm,素片重量为0.61g-0.68g;
步骤F、将所述薄膜包衣剂用纯化水溶解,配制8-12wt%的包衣液,将所述素片包衣,得到压片糖果。
该制备方法工序通过混合、造粒、压片、包衣,使所得产品稳定性好,并且食用方便,口味适中。采用三维混合机进行混合,不仅对颗粒物料的磨损和压馈微小,对热敏性物料混合不发生过热反应,且混合的制剂稳定,不发生分层及离析现象。
具体实施方式
为了使本发明的目的、技术方案及优点更加清楚明白,以下结合实施例,对本发明进行进一步详细说明。应当理解,此处所描述的具体实施例仅仅用以解释本发明,并不用于限定本发明。
实施例1
本发明实施例提供一种视力脑力养护压片糖果,原料按质量百分比计,包括以下组分:酸枣仁提取物:11.54份,百合提取物:7.69份,莲子提取物:7.69份,改性大豆磷脂粉:7.69份,磷虾油粉:3.85份,叶黄素酯:2.77份,白葡萄粉:2份,山梨糖醇:28.31份,麦芽糊精:25.38份,硬脂酸镁:1.08份,羟丙基甲基纤维素:2份。其中,叶黄素酯来自德国科宁,薄膜包衣剂为羟丙基甲基纤维素。
上述视力脑力养护压片糖果的制备方法,包括以下步骤:
步骤A、按照上述的原料配比称取各组分;
步骤B、将所述酸枣仁提取物、百合提取物、莲子提取物、改性大豆磷脂粉、磷虾油粉、叶黄素酯、白葡萄粉、麦芽糊精预混处理,得到预混料;
步骤C、将所述预混料与体积浓度为80%乙醇混合,所述预混料与乙醇的质量比为10:3,制得软材,将软材过16目筛制粒、干燥、过14目筛整粒,得到颗粒;
步骤D、将所述山梨糖醇、硬脂酸镁与所述颗粒采用三维混合机,混合20min,得到总混料;
步骤E、将所述总混料以直径12mm浅凹冲压片,得到素片,素片重量为0.65g;
步骤F、将所述羟丙基甲基纤维素用纯化水溶解,配制10wt%的包衣液,将所述素片包衣,包衣增重2份,得到压片糖果。
其中,上述酸枣仁提取物的制备方法如下:
将酸枣仁洗净、烘干、粉碎过80目筛,以10倍量的纯化水浸泡7h,煎煮2次,每次2h,合并煎煮液,过滤,将滤液在真空度为-0.06Mpa~-0.08Mpa,温度为60~65℃条件下减压浓缩,得到相对密度为1.08-1.12膏粉状酸枣仁提取物。
其中,上述百合提取物的制备方法如下:
将百合洗净、烘干、粉碎过60目筛,以10倍量的纯化水浸泡7h,采用超声萃取2次,每次功率为400-500W,每次超声时间为15min,过滤,将滤液在喷雾干燥得到百合提取物。
其中,上述莲子提取物的制备方法如下:
将莲子洗净、烘干,粉碎,以10倍量的纯化水浸泡7h,然后于80℃提取3次,每次3h,合并提取液,过滤,将滤液在喷雾干燥得到莲子提取物。
实施例2
本发明实施例提供一种视力脑力养护压片糖果,原料按质量百分比计,包括以下组分:酸枣仁提取物:10份,百合提取物:7.5份,莲子提取物:8.5份,改性大豆磷脂粉:8.5份,磷虾油粉:2.5份,叶黄素酯:1.5份,白葡萄粉:1份,山梨糖醇:30份,麦芽糊精:27份,硬脂酸镁:1.5份,羟丙基甲基纤维素:2份。其中,叶黄素酯来自德国科宁,薄膜包衣剂为羟丙基甲基纤维素。
上述视力脑力养护压片糖果的制备方法,包括以下步骤:
步骤A、按照上述的原料配比称取各组分;
步骤B、将所述酸枣仁提取物、百合提取物、莲子提取物、改性大豆磷脂粉、磷虾油粉、叶黄素酯、白葡萄粉、麦芽糊精预混处理,得到预混料;
步骤C、将所述预混料与体积浓度为75%乙醇混合,所述预混料与乙醇的质量比为10:3.5,制得软材,将软材过16目筛制粒、干燥、过14目筛整粒,得到颗粒;
步骤D、将所述山梨糖醇、硬脂酸镁与所述颗粒采用三维混合机,混合22min,得到总混料;
步骤E、将所述总混料以直径12mm浅凹冲压片,得到素片,素片重量为0.67g;
步骤F、将所述羟丙基甲基纤维素用纯化水溶解,配制12wt份的包衣液,将所述素片包衣,包衣增重2.2份,得到压片糖果。
其中,上述酸枣仁提取物的制备方法如下:
将酸枣仁洗净、烘干、粉碎过80目筛,以8倍量的纯化水浸泡8h,煎煮3次,每次3h,合并煎煮液,过滤,将滤液在真空度为-0.06Mpa~-0.08Mpa,温度为60~65℃条件下减压浓缩,得到相对密度为1.08-1.12膏粉状酸枣仁提取物。
其中,上述百合提取物的制备方法如下:
将百合洗净、烘干、粉碎过60目筛,以9倍量的纯化水浸泡8h,采用超声萃取2次,每次功率为400-500W,每次超声时间为18min,过滤,将滤液在喷雾干燥得到百合提取物。
其中,上述莲子提取物的制备方法如下:
将莲子洗净、烘干,粉碎,以8倍量的纯化水浸泡8h,然后于90℃提取3次,每次3.5h,合并提取液,过滤,将滤液在喷雾干燥得到莲子提取物。
实施例3
本发明实施例提供一种视力脑力养护压片糖果,原料按质量百分比计,包括以下组分:酸枣仁提取物:13份,百合提取物:8.5份,莲子提取物:6.5份,改性大豆磷脂粉:7.5份,磷虾油粉:4.5份,叶黄素酯:3.5份,白葡萄粉:4份,山梨糖醇:26份,麦芽糊精:22份,硬脂酸镁:1.5份,羟丙基甲基纤维素:3份。其中,叶黄素酯来自德国科宁,薄膜包衣剂为羟丙基甲基纤维素。
上述视力脑力养护压片糖果的制备方法,包括以下步骤:
步骤A、按照上述的原料配比称取各组分;
步骤B、将所述酸枣仁提取物、百合提取物、莲子提取物、改性大豆磷脂粉、磷虾油粉、叶黄素酯、白葡萄粉、麦芽糊精预混处理,得到预混料;
步骤C、将所述预混料与体积浓度为85%乙醇混合,所述预混料与乙醇的质量比为10:2.5,制得软材,将软材过16目筛制粒、干燥、过14目筛整粒,得到颗粒;
步骤D、将所述山梨糖醇、硬脂酸镁与所述颗粒采用三维混合机,混合18min,得到总混料;
步骤E、将所述总混料以直径12mm浅凹冲压片,得到素片,素片重量为0.62g;
步骤F、将所述羟丙基甲基纤维素用纯化水溶解,配制8wt份的包衣液,将所述素片包衣,包衣增重2份,得到压片糖果。
其中,上述酸枣仁提取物的制备方法如下:
将酸枣仁洗净、烘干、粉碎过80目筛,以9倍量的纯化水浸泡8h,煎煮3次,每次2.5h,合并煎煮液,过滤,将滤液在真空度为-0.06Mpa~-0.08Mpa,温度为60~65℃条件下减压浓缩,得到相对密度为1.08-1.12膏粉状酸枣仁提取物。
其中,上述百合提取物的制备方法如下:
将百合洗净、烘干、粉碎过60目筛,以8倍量的纯化水浸泡8h,采用超声萃取2次,每次功率为400-500W,每次超声时间为20min,过滤,将滤液在喷雾干燥得到百合提取物。
其中,上述莲子提取物的制备方法如下:
将莲子洗净、烘干,粉碎,以12倍量的纯化水浸泡6h,然后于100℃提取2次,每次3.5h,合并提取液,过滤,将滤液在喷雾干燥得到莲子提取物。
对比例1
本对比例提供一种视力脑力养护压片糖果,原料按质量百分比计,包括以下组分:酸枣仁提取物:11.54份,茯苓:7.69份,莲子提取物:7.69份,改性大豆磷脂粉:7.69份,磷虾油粉:3.85份,叶黄素酯:2.77份,白葡萄粉:2份,山梨糖醇:28.31份,麦芽糊精:25.38份,硬脂酸镁:1.08份,羟丙基甲基纤维素:2份。其中,薄膜包衣剂为羟丙基甲基纤维素。
上述视力脑力养护压片糖果的制备方法如实施例1所述,不在赘述。
对比例2
本对比例提供一种视力脑力养护压片糖果,原料按质量百分比计,包括以下组分:黄精:11.54份,百合提取物:7.69份,莲子提取物:7.69份,改性大豆磷脂粉:7.69份,磷虾油粉:3.85份,叶黄素酯:2.77份,白葡萄粉:2份,山梨糖醇:28.31份,麦芽糊精:25.38份,硬脂酸镁:1.08份,羟丙基甲基纤维素:2份。其中,薄膜包衣剂为羟丙基甲基纤维素。
上述视力脑力养护压片糖果的制备方法如实施例1所述,不在赘述。
为了更好的说明本发明实施例提供的视力脑力养护压片糖果的特性,下面将实施例1、2、3与对比例1、2制备的视力脑力养护压片糖果应用于临床。
临床资料:
一般资料:按照卫生部颁发的《保健食品检验与评价技术规范实施手册》选择受试者对象,年龄在21-45岁之间长期进行复杂的脑力劳动,经常出现头昏脑胀,记忆力下降,注意力涣散,失眠多梦且长期用眼容易产生视疲劳受试对象300人,随机分成第一实验组、第二实验组、第三实验组、第一对比组、第二对比组和空白对照组,各组50人,6组一般资料比较差异无统计学意义(P>0.05),具有可比性。
治疗方法:第一实验组、第二实验组、第三实验组分别服用本发明实施例1、实施例2、实施例3制备的视力脑力养护压片糖果,每日2次,每次2片,连续服用60天。将第一对比组、第二对比组分别服用对比例1、对比例2制备的视力脑力养护压片糖果,每日2次,每次2片,连续服用60天。空白对照组不服用任何药物。
治疗判断标准:
治愈:不再有睡眠障碍、精神充沛、记忆力明显提高,注意力集中,由长期进行复杂脑力劳动引起的体征及症状完全消失,且长时间用眼引起的眼酸、眼涩、视物模糊、流泪、眼胀、异物感、全身不适8中主要临床症状完全消失。
显效:睡眠较好,精神较好,由长期进行复杂脑力劳动引起的体征及症状有明显改善,且长时间用眼引起的眼酸、眼涩、视物模糊、流泪、眼胀、异物感、全身不适8中主要临床症状明显改善。
有效:能自主睡眠,由长期进行复杂脑力劳动引起的体征及症状有所减轻,且长时间用眼引起的眼酸、眼涩、视物模糊、流泪、眼胀、异物感、全身不适8中主要临床症状有所减轻。
无效:体征无改变,症状如前。
治疗结果:第一实验组、第二实验组、第三实验组、第一对比组、第二对比组和空白对照组的治疗结果如下表1所示。
表1治疗结果
由表1可以明显看出,试验组包括第一实验组、第二实验组、第三实验组的总有效率为96份以上,治愈率64份以上。3组实验组的治愈率和总有效率与空白对照组比较差异有统计学意义(P<0.05),实验组明显优于空白对照组。
对比组包括第一对比组、第二对比组的总有效率为50份以上,治愈率为22份以上,2组对比组的治愈率和总有效率与空白对照组比较差异有统计学意义(P<0.05)。但是与实验组相比,实验组的治愈率和总有效率明显优于对比组。
本发明的视力脑力养护压片糖果食用前后,血常规、尿常规、便常规及血生化指标均在正常范围,说明本品对受试者身体健康无不良影响,且试验过程中未发现过敏及其他不良反应。
以上所述仅为本发明的较佳实施例而已,并不用以限制本发明,凡在本发明的精神和原则之内所作的任何修改、等同替换或改进等,均应包含在本发明的保护范围之内。
Claims (10)
1.一种养护视力脑力的组合物,其特征在于:包括以下重量份数配比的原料:酸枣仁提取物:10-13份,百合提取物:6.5-8.5份,莲子提取物:6.5-8.5份,改性大豆磷脂粉:6.5-8.5份,磷虾油粉:2.5-4.5份,叶黄素酯:1.5-3.5份,白葡萄粉:1-4份。
2.如权利要求1所述的养护视力脑力的组合物,其特征在于:包括以下重量份数配比的原料:酸枣仁提取物:11.54份,百合提取物:7.69份,莲子提取物:7.69份,改性大豆磷脂粉:7.69份,磷虾油粉:3.85份,叶黄素酯:2.77份,白葡萄粉:2份。
3.如权利要求1所述的养护视力脑力的组合物,其特征在于:所述酸枣仁提取物的制备方法如下:
将酸枣仁洗净、烘干、粉碎过80目筛,以8-12倍量的纯化水浸泡6-8h,煎煮2-3次,每次2-3h,合并煎煮液,过滤,将滤液在真空度为-0.06Mpa~-0.08Mpa,温度为60~65℃条件下减压浓缩,得到相对密度为1.08-1.12膏粉状酸枣仁提取物。
4.如权利要求1所述的养护视力脑力的组合物,其特征在于:所述百合提取物的制备方法如下:
将百合洗净、烘干、粉碎过60目筛,以8-10倍量的纯化水浸泡6-8h,采用超声萃取1-2次,每次功率为400-500W,每次超声时间为15-20min,过滤,将滤液再喷雾干燥得到百合提取物。
5.如权利要求1所述的养护视力脑力的组合物,其特征在于:所述莲子提取物的制备方法如下:
将莲子洗净、烘干,粉碎,以8-12倍量的纯化水浸泡6-8h,然后于80-100℃提取2-3次,每次3-4h,合并提取液,过滤,将滤液再喷雾干燥得到莲子提取物。
6.如权利要求1所述的养护视力脑力的组合物,其特征在于:所述叶黄素酯为含量为5-10wt%的叶黄素酯微囊或叶黄素酯粉末;和/或
所述白葡萄粉中总多酚含量为70-74wt%。
7.如权利要求1-6任一项所述的养护视力脑力的组合物在制备养护视力脑力食品中的应用。
8.一种视力脑力养护压片糖果,其特征在于:包括如权利要求1-6任一项所述的养护视力脑力的组合物。
9.如权利要求8所述的视力脑力养护压片糖果,其特征在于:还包括以下重量份数配比的原料:山梨糖醇:25-30份,麦芽糊精:22-27份,硬脂酸镁:0.5-1.5份,薄膜包衣剂:1-3份。
10.如权利要求8或9所述的视力脑力养护压片糖果的制备方法,其特征在于:至少包括以下步骤:
步骤A、按照如权利要求8-9任一项所述的原料配比称取各组分;
步骤B、将所述酸枣仁提取物、百合提取物、莲子提取物、改性大豆磷脂粉、磷虾油粉、叶黄素酯、白葡萄粉、麦芽糊精采用三维混合机,混合28-32min,得到预混料;
步骤C、将所述预混料与体积浓度为75-85%的乙醇混合制得软材,且所述预混料与乙醇的质量比为10:(2.5-3.5),将所述软材过16目筛制粒、干燥、过14目筛整粒,得到颗粒;
步骤D、将所述山梨糖醇、硬脂酸镁与所述颗粒采用三维混合机,混合18-22min总混处理,得到总混料;
步骤E、将所述总混料压片,得到素片;
步骤F、将所述薄膜包衣剂用纯化水溶解,配制8-12wt%的包衣液,将所述素片包衣,得到压片糖果。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810582800.7A CN108720016A (zh) | 2018-06-07 | 2018-06-07 | 一种养护视力脑力的组合物及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810582800.7A CN108720016A (zh) | 2018-06-07 | 2018-06-07 | 一种养护视力脑力的组合物及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108720016A true CN108720016A (zh) | 2018-11-02 |
Family
ID=63932368
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810582800.7A Pending CN108720016A (zh) | 2018-06-07 | 2018-06-07 | 一种养护视力脑力的组合物及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108720016A (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101804148A (zh) * | 2009-02-16 | 2010-08-18 | 北京因科瑞斯医药科技有限公司 | 一种具有改善睡眠功能的药物组合物及其制备方法 |
-
2018
- 2018-06-07 CN CN201810582800.7A patent/CN108720016A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101804148A (zh) * | 2009-02-16 | 2010-08-18 | 北京因科瑞斯医药科技有限公司 | 一种具有改善睡眠功能的药物组合物及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102919450B (zh) | 一种五谷浸提液凉茶及其制备方法 | |
CN112869162A (zh) | 一种具有抗疲劳、改善睡眠功能的组合物及制备方法 | |
CN107242527B (zh) | 一种适用于中老年人食用玫瑰酱的制备方法 | |
CN103082170A (zh) | 一种适合糖尿病人食用的合成大米 | |
CN104432036A (zh) | 缓解视疲劳的保健营养组合物及其制备方法与应用 | |
CN109549097A (zh) | 一种具有降糖降脂功能的保健面条 | |
CN105232907A (zh) | 一种补肾壮阳饮料及其制备方法 | |
CN109497227A (zh) | 一种红糖杞枣保健姜茶 | |
CN1939520A (zh) | 一种可改善记忆的益智胶囊及其制备工艺 | |
CN106923130A (zh) | 含西红花的固体饮料、其制备方法及应用 | |
CN104940645A (zh) | 一种具有美容养颜功能的铁皮石斛中药组合物及其制剂 | |
CN109528953A (zh) | 一种对人体微循环具有改善作用的渡草集中药植物组合物 | |
CN107996726A (zh) | 奇亚籽植物蛋白饮料及其制备方法 | |
CN105212040A (zh) | 一种含黑玉米的复合营养粉及其制备方法 | |
CN106072132A (zh) | 一种大枣食品 | |
CN110279773A (zh) | 一种气虚型体质补气健脾、益肾强志的中药组合物 | |
CN109673802A (zh) | 一种磷脂酰丝氨酸益智仁压片糖果及制备方法和应用 | |
CN109123621A (zh) | 一种可调节机体免疫功能抑制血糖升高的保健食品 | |
CN101889685B (zh) | 一种天然植物保健品及制备方法 | |
CN101804018A (zh) | 一种具有祛黄褐斑功能的中药面膜粉及其制备方法 | |
CN105559076B (zh) | 一种备孕期男性全营养药膳餐糊 | |
CN108720016A (zh) | 一种养护视力脑力的组合物及其制备方法和应用 | |
CN103734609B (zh) | 增强心脑供血,供氧,健脾补气,养血补肾药食同膳面 | |
CN1565205A (zh) | 睡奶 | |
CN110507770A (zh) | 一种双叶薏枣清降代用茶 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20200525 Address after: 476000 No. 12, Yongan street, Liang Yuan Park, Henan, Shangqiu Applicant after: Sun Yutong Address before: 101300, No. two, 1 road, Shunyi Park, Zhongguancun science and Technology Park, Beijing, Shunyi District Applicant before: ZHONGTAI YIJIA HEALTH TECHNOLOGY (BEIJING) Co.,Ltd. |
|
TA01 | Transfer of patent application right | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20181102 |
|
WD01 | Invention patent application deemed withdrawn after publication |